AmniSure

Germantown, United States Founded: 2005 • Age: 21 yrs Acquired By Qiagen
Diagnostic immunoassay for detection of Rupture of Membranes in pregnant women
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About AmniSure

AmniSure is a company based in Germantown (United States) founded in 2005 was acquired by Qiagen in May 2012. AmniSure operates in a competitive market with competitors including Natera, BillionToOne, SYNLAB, Progenity and Auxogyn, among others.

  • Headquarter Germantown, United States
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Health Technology & Digital Health Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    Qiagen

    (May 03, 2012)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of AmniSure

Premium access

Detailed funding history for AmniSure

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in AmniSure

AmniSure has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Qiagen.

All
Institutional
Investor Description Founded Year Domain Location
Products and reagents for molecular diagnostic assays are supplied.
Locked Locked Locked
Premium access

Investor details for AmniSure

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by AmniSure

Investments
Premium access

Investment portfolio details for AmniSure

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - AmniSure

Premium access

Detailed financials for AmniSure

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Amnisure Comparisons

AmniSure Primary company
Description
Diagnostic immunoassay for detection of Rupture of Membranes...
Location
Germantown, United States
Founded Year
2005
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for AmniSure

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of AmniSure

AmniSure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, BillionToOne, SYNLAB, Progenity and Auxogyn, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of cell-free DNA testing for oncology, women’s health, and organ health
Locked Locked Locked
Provider of cell-free cancer liquid biopsy test
Locked Locked Locked
Provider of medical diagnosis and clinical laboratory analysis services
Locked Locked Locked
Non-invasive prenatal genomic testing is provided for genetic disorders.
Locked Locked Locked
Diagnostic technologies for IVF embryo viability assessment are developed.
Locked Locked Locked
Sensitive multiplex platforms for QPCR are developed using toehold probes.
Premium access

Detailed competitors of AmniSure

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Amnisure

Premium access

Complete news archive for AmniSure

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about AmniSure

AmniSure was founded in 2005.

AmniSure is headquartered in Germantown, United States.

Michael Friedman is the current CEO of AmniSure.

AmniSure was founded in 2005 in Germantown, United States, and operates in the medical diagnostics sector focused on obstetrics. A proprietary test, the AmniSure ROM Test, is developed and marketed to identify premature rupture of fetal membranes through detection of the PAMG-1 protein marker in amniotic fluid. This addresses a condition affecting about 10 of pregnancies and 30 of preterm cases.

AmniSure's top competitors include Natera, BillionToOne and Overture Life.

AmniSure has 1 investor. Key investors include Qiagen.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available